CD8A and neoplasm: Here, we observed that BVAC-K1117 vaccination that can induce diverse tumor-specific CD8+ T cells against ICD epitopes as well as ECD epitopes of the HER2 antigen showed enhanced antitumor effects when combined with anti-PD-L1 checkpoint blockade therapy.